提高 (18)F-FDOPA PET 对胶质瘤管理的可行性和实用性。
Increasing feasibility and utility of (18)F-FDOPA PET for the management of glioma.
机构信息
CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia; The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia.
CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia.
出版信息
Nucl Med Biol. 2015 Oct;42(10):788-95. doi: 10.1016/j.nucmedbio.2015.06.001. Epub 2015 Jun 9.
INTRODUCTION
Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with (18)F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of (18)F-DOPA imaging grants utility for a number of clinical applications.
METHODS
A collection of published work about (18)F-FDOPA PET was made and a critical review was discussed and written.
RESULTS
A number of research papers have been published demonstrating that in conjunction with MRI, (18)F-FDOPA PET provides greater sensitivity and specificity than these modalities in detection, grading, prognosis and validation of treatment success in both primary and recurrent gliomas. In further comparisons with (11)C-MET, (18)F-FLT, (18)F-FET and MRI, (18)F-FDOPA has shown similar or better efficacy. Recently synthesis cassettes have become available, making (18)F-FDOPA more accessible.
CONCLUSIONS
According to the available data, (18)F-FDOPA PET is a viable radiotracer for imaging and treatment planning of gliomas.
ADVANCES IN KNOWLEDGE AND IMPLICATION FOR PATIENT CARE
(18)F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis and treatment planning of gliomas cases, improving on that of MRI and (18)F-FDG PET.
简介
尽管采用了激进的治疗方法，神经胶质瘤仍然预后不良。被诊断为 IV 级神经胶质瘤（胶质母细胞瘤；GBM）的患者通常在两年内死亡，即使是 III 级间变性神经胶质瘤和 II 级神经胶质瘤的患者，其预后也分别为 2-5 年和 2 年。（18）F-FDOPA 的 PET 成像允许对胶质瘤相对于周围组织的代谢进行体内评估。（18）F-DOPA 成像的高灵敏度为许多临床应用提供了实用价值。
方法
收集了有关（18）F-FDOPA PET 的已发表文献，并对其进行了批判性回顾和讨论。
结果
已发表了许多研究论文，证明与 MRI 结合使用时，（18）F-FDOPA PET 在原发性和复发性神经胶质瘤的检测、分级、预后和治疗效果验证方面比这些模态具有更高的敏感性和特异性。在与（11）C-MET、（18）F-FLT、（18）F-FET 和 MRI 的进一步比较中，（18）F-FDOPA 显示出相似或更好的疗效。最近，合成盒已经可用，使（18）F-FDOPA 更容易获得。
结论
根据现有数据，（18）F-FDOPA PET 是一种可行的神经胶质瘤成像和治疗计划放射性示踪剂。
知识进展及其对患者护理的影响
（18）F-FDOPA PET 似乎是一种可行的放射性药物，可用于诊断和治疗计划神经胶质瘤病例，优于 MRI 和（18）F-FDG PET。
Zotero 插件